French firm Vivalis has announced the first data evaluating its
proprietary EBx cell lines for the production of monoclonal
antibodies (MAbs), with initial results suggesting high cytotoxic
properties in the resultant MAbs.
Just weeks after announcing intentions to snap up biologics firm
MedImmune, AstraZeneca has acquired DSM's old biologics
manufacturing facility in Montreal, Canada, a site that's been
gathering dust since it was mothballed...
A firm specialising in disposable equipment for the
biopharmaceutical industry has introduced a new revamped bioreactor
to its catalogue, dispensing with the traditional rocking and
rolling mechanisms used in many bioreactors.
Moving from egg-based production of vaccines to the use of
cell-culture technologies in existing manufacturing plants is
cheaper and quicker than building new facilities to handle a flu
pandemic within the next five years, new research...